Medartis in the news

Medartis Holding AG will present its 2025 financial results and 2026 outlook in a hybrid event led by its CEO and new CFO, highlighting its global presence in surgical bone fixation devices.

Medartis, specializing in surgical implants, saw major stock gains in 2025 under new CEO Matthias Schupp's leadership.

Peter Hackel, with strong medtech experience and industry connections, is the new CFO of Medartis expecting a smooth transition.

Medartis focuses on surgical implants for bone injuries and plans US expansion despite political challenges.

Medartis is expanding its US manufacturing and surgical training presence while scaling its award-winning thumb prostheses and 3D-printed titanium implants.

Medartis has been awarded the 2026 Swiss Medtech Award for its innovation in high-precision titanium implant systems and surgical technology.

Medartis Holding AG received the Swiss Medtech Award 2026 for its innovations in titanium medical devices and surgical fixation solutions.

Medartis maintains strong revenue growth guidance and product momentum in specialized implants while analysts view the current stock price as significantly undervalued.

Medartis details its 2026 strategic roadmap and innovation pipeline for titanium orthopedic devices in the upper extremities and hand markets.

Medartis is accelerating its orthopedic business growth through acquisitions and a multi-brand strategy targeting 2026.

Medartis grew its revenue to 269 million francs in 2025 and is acquiring 3D-printing specialist Cadskills to expand its titanium implant portfolio.

Medartis met sales expectations with 16% organic growth but posted a soft financial outlook despite strategic acquisitions in personalized titanium implants.

Medartis Holding has outperformed the market with a 66% five-year stock return driven by consistent 13% annual revenue growth and a shift toward profitability.

Medartis will present its 2025 financial results and 2026 outlook at a March 2026 conference accessible both in person and online.

Medartis will present its 2025 financial results and 2026 outlook in a hybrid event on March 17, 2026, featuring CEO Matthias Schupp and new CFO Peter Hackel.

Medartis Holding AG is currently trading at fair value with a strong 43% revenue growth forecast and high stock price volatility.

Medartis names Dr. Peter Hackel as CFO from 2026, bringing broad leadership experience amid company growth through acquisitions.

Peter Hackel is appointed CFO of Medartis Group starting January 1, succeeding Dirk Kirsten who will pursue new projects.

Medartis CFO Dirk Kirsten will leave in 2026, with Peter Hackel appointed as his successor amid company growth through acquisitions.

LLB and Medartis appointed new CFOs, with Medartis naming Peter Hackel as CFO starting 2026 amid recent acquisitions.